Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
75 hedge funds and large institutions have $632M invested in Rubius Therapeutics, Inc in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
9% more funds holding
Funds holding: 69 → 75 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less call options, than puts
Call options by funds: $758K | Put options by funds: $785K
49% less capital invested
Capital invested by funds: $1.23B → $632M (-$599M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$4.66M |
| 2 |
BlackRock
New York
|
+$4.47M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$3.52M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.85M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.37M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.26M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$567K |
| 4 |
Jennison Associates
New York
|
-$511K |
| 5 |
Millennium Management
New York
|
-$361K |
RUBY Hedge Fund Activity: Q3 2019 in Review
75 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2019, worth a combined $632M — down 49% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RUBY positions and 4 closed out — a net gain of 6 holders — while 30 added to existing stakes and 14 trimmed.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $4.66M. The largest seller was EcoR1 Capital, cutting an estimated $2.37M.
- 75 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2019, up from 69 in Q2 2019.
- Funds reported $632M of Rubius Therapeutics, Inc stock for Q3 2019, down 49% quarter-over-quarter.
- 10 funds opened new Rubius Therapeutics, Inc positions in Q3 2019 and 4 closed out, a net change of +6 holders.
- The largest Rubius Therapeutics, Inc buyer in Q3 2019 was Alkeon Capital Management, an estimated $4.66M added.
- The largest Rubius Therapeutics, Inc seller in Q3 2019 was EcoR1 Capital, an estimated $2.37M sold.
Based on aggregated 13F filings for Q3 2019.